No Data
Lionco Pharmaceutical Group (603669) Investment Value Analysis Report: The performance low point has passed, multiple businesses drive new development.
The tenth batch of centralized procurement work has been initiated, and the company has two products that meet the requirements for participation. In October 2024, the tenth batch of national organized centralized procurement of pharmaceuticals will start, involving 62 products and 263 specifications, mainly in therapeutic areas.
Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.
Lionco Pharmaceutical Group (603669.SH): Subsidiary participates in the national pharmaceutical centralized procurement and plans to be selected.
On December 13, Gelonghui reported that Lionco Pharmaceutical Group (603669.SH) announced that its wholly-owned subsidiary Hainan Lionco Pharmaceutical Co., Ltd. participated in the tenth batch of national centralized procurement organized by the National Organization for Pharmaceutical Joint Procurement Office (referred to as the 'Joint Procurement Office'). According to the public announcement of the proposed selection results of national centralized procurement released by the Joint Procurement Office, Lionco Pharmaceutical's product, injectable ceftazidime sodium, is proposed to be selected for this centralized procurement. The sales revenue of injectable ceftazidime sodium from Lionco Pharmaceutical's wholly-owned subsidiary in 2023 amounted to 0 million yuan, accounting for 0% of the company's revenue for the year 2023; sales for the first three quarters of 2024.
Express News | Lionco Pharmaceutical Group: The subsidiary's product, injectable ceftriaxone sodium, is proposed to be selected for national centralized pharmaceutical procurement.
Company Report for the Third Quarter of 2024 (after correction)
Announcement on additional information to the 2024 Third Quarter Report
No Data
